

References

I-234

1. Kushner BH, Cheung IY, Modak S, et al. Humanized 3F8 Anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma a phase I clinical trial. *JAMA Oncol.* 2018;4(12):1729-1935.
2. Sujitjoo J, Sayour E, Tsao ST, et al. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma- assessing tumor and T cell interaction. *Translational Oncology.* 2021;1-11.
3. Danyelza® (naxitamab), for intravenous use [package insert]. Y-mAbs Therapeutics, Inc. New York, NY. Revised 11/2020.
4. Clinical Pharmacology™ Tampa FL: Gold Standard, Inc. Naxitamab. 2022.
5. Micromedex®Solutions Compendia. 2022.
6. Naxitamab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 25, 2021.